Skip to content

Study · Animal study (in vivo) · rat · 1983

6 results

Dermorphin: cardiovascular and sympathetic modulation in the anteroventral hypothalamus of conscious rats.

Feuerstein G, Faden AI

Life sciences1 Jan 1983Cited by 3 (Europe PMC)

PMID6664249 (opens in a new tab)DOI10.1016/0024-3205(83)90606-9 (opens in a new tab)PepBankPUB-06664249
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In conscious rats, dermorphin microinjection elicited tachycardia at the lower dose.

    In plain wordsIn rats, the lower dermorphin dose increased heart rate.

    Peptide
    Dermorphin
    Outcome
    IncreaseHeart rate
    Study

    ratn: not reported in source

    conscious rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 pmol · microinjection into nucleus preopticus medialisAs given in this study (rat).

    Source sentences

    Summary
    Microinjections of 10 pmol of dermorphin into the nucleus preopticus medialis (POM) elicited tachycardia without changing the mean blood pressure (MBP).
    1 context sentence
    Summary · context
    Cardiovascular and sympathetic responses to hypothalamic injections of dermorphin were studied in conscious rats.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In conscious rats, lower-dose dermorphin did not change mean blood pressure.

    In plain wordsIn rats, the lower dermorphin dose did not change mean blood pressure.

    Peptide
    Dermorphin
    Outcome
    No significant changeMean blood pressure
    Study

    ratn: not reported in source

    conscious rats
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 pmol · microinjection into nucleus preopticus medialisAs given in this study (rat).

    Source sentences

    Summary
    Microinjections of 10 pmol of dermorphin into the nucleus preopticus medialis (POM) elicited tachycardia without changing the mean blood pressure (MBP).
    1 context sentence
    Summary · context
    Cardiovascular and sympathetic responses to hypothalamic injections of dermorphin were studied in conscious rats.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In conscious rats, higher-dose dermorphin caused prolonged tachycardia.

    In plain wordsIn rats, the higher dermorphin dose caused a prolonged increase in heart rate.

    Peptide
    Dermorphin
    Outcome
    IncreaseHeart rate
    Study

    ratn: not reported in source

    conscious rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    100 pmol · microinjection into nucleus preopticus medialisAs given in this study (rat).

    Source sentences

    Summary
    A higher dose of dermorphin (100 pmol) caused prolonged tachycardia, and an increase in MBP.
    1 context sentence
    Summary · context
    Cardiovascular and sympathetic responses to hypothalamic injections of dermorphin were studied in conscious rats.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In conscious rats, higher-dose dermorphin increased mean blood pressure.

    In plain wordsIn rats, the higher dermorphin dose increased mean blood pressure.

    Peptide
    Dermorphin
    Outcome
    IncreaseMean blood pressure
    Study

    ratn: not reported in source

    conscious rats
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    100 pmol · microinjection into nucleus preopticus medialisAs given in this study (rat).

    Source sentences

    Summary
    A higher dose of dermorphin (100 pmol) caused prolonged tachycardia, and an increase in MBP.
    1 context sentence
    Summary · context
    Cardiovascular and sympathetic responses to hypothalamic injections of dermorphin were studied in conscious rats.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In conscious rats, the dermorphin pressor/tachycardic period involved increased plasma norepinephrine.

    In plain wordsIn rats, blood norepinephrine increased during the dermorphin blood pressure and heart rate response.

    Peptide
    Dermorphin
    Outcome
    IncreasePlasma norepinephrine
    Study

    ratn: not reported in source

    conscious rats
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    100 pmol · microinjection into nucleus preopticus medialisAs given in this study (rat).

    Source sentences

    Summary
    The pressor/tachycardic period following injection of 100 pmol dermorphin was accompanied by increased levels of plasma norepinephrine and epinephrine.
    1 context sentence
    Summary · context
    Cardiovascular and sympathetic responses to hypothalamic injections of dermorphin were studied in conscious rats.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In conscious rats, the dermorphin pressor/tachycardic period involved increased plasma epinephrine.

    In plain wordsIn rats, blood epinephrine increased during the dermorphin blood pressure and heart rate response.

    Peptide
    Dermorphin
    Outcome
    IncreasePlasma epinephrine
    Study

    ratn: not reported in source

    conscious rats
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    100 pmol · microinjection into nucleus preopticus medialisAs given in this study (rat).

    Source sentences

    Summary
    The pressor/tachycardic period following injection of 100 pmol dermorphin was accompanied by increased levels of plasma norepinephrine and epinephrine.
    1 context sentence
    Summary · context
    Cardiovascular and sympathetic responses to hypothalamic injections of dermorphin were studied in conscious rats.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.